Finally, we prioritised compounds to be tested in vivo using AI-based network propagation and show that single-agent SRC inhibition with saracatinib extend survival of our mesothelioma genetically-engineered mouse model well beyond the cisplatin/pemetrexed combination. This evidence concerns the gene SRC and mesothelioma.